التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of vaccine efficacy with 2B/T epitope conjugated porcine IgG-Fc recombinants against foot-and-mouth disease virus. |
| المؤلفون: |
Song BM; Laboratory for Infectious Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University., Lee GH; Laboratory for Infectious Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University., Kang SM; Laboratory for Infectious Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University., Tark D; Laboratory for Infectious Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University. |
| المصدر: |
The Journal of veterinary medical science [J Vet Med Sci] 2024 Jul 29. Date of Electronic Publication: 2024 Jul 29. |
| Publication Model: |
Ahead of Print |
| نوع المنشور: |
Journal Article |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: Japanese Society Of Veterinary Science Country of Publication: Japan NLM ID: 9105360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1347-7439 (Electronic) Linking ISSN: 09167250 NLM ISO Abbreviation: J Vet Med Sci Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Tokyo : Japanese Society Of Veterinary Science |
| مستخلص: |
The inactivated vaccine is effective in controlling foot-and-mouth disease (FMD), but it has drawbacks such as the need for a biosafety level 3 laboratory facility to handle live foot-and-mouth disease virus (FMDV), high production costs, and biological safety risks. In response to these challenges, we developed a new recombinant protein vaccine (2BT-pIgG-Fc) containing porcine IgG-Fc to enhance protein stability in the body. This vaccine incorporates two-repeat B-cell and one-single T-cell epitope derived from O/Jincheon/SKR/2014. Our study confirmed that 2BT-pIgG-Fc and a commercial FMDV vaccine induced FMDV-specific antibodies in guinea pigs at 28 days post-vaccination. The percentage inhibition (PI) value of 2BT-pIgG-Fc was 90.43%, and the commercial FMDV vaccine was 81.75%. The PI value of 2BT-pIgG-Fc was 8.68% higher than that of commercial FMDV vaccine. In pigs, the primary target animals for FMDV, all five individuals produced FMDV-specific antibodies 42 days after vaccination with 2BT-pIgG-Fc. Furthermore, serum from 2BT-pIgG-Fc-vaccinated pigs exhibited neutralizing ability against FMDV infection. Intriguingly, the 2BT-pIgG-Fc recombinant demonstrated FMDV-specific antibody production rates and neutralization efficiency similar to commercial inactivated vaccines. This study illustrates the potential to enhance vaccine efficacy by strategically combining well-known antigenic domains in the development of recombinant protein-based vaccines. |
| فهرسة مساهمة: |
Keywords: B-cell epitope; T-cell epitope; foot-and-mouth disease virus; porcine immunoglobulin G fragment crystallizable region; recombinant protein vaccine |
| تواريخ الأحداث: |
Date Created: 20240728 Latest Revision: 20240728 |
| رمز التحديث: |
20240729 |
| DOI: |
10.1292/jvms.23-0480 |
| PMID: |
39069487 |
| قاعدة البيانات: |
MEDLINE |
